CLEARMIND MEDICINE ANNOUNCES ADDITIONAL TOPLINE POSITIVE SAFETY RESULTS REINFORCING FAVORABLE PROFILE OF CMND-100 IN ONGOING PHASE I/IIA CLINICAL TRIAL
CLEARMIND MEDICINE INC - ANNOUNCES POSITIVE SAFETY RESULTS FROM PHASE I/IIA TRIAL
CLEARMIND MEDICINE INC - SAFETY DATA SHOW NO SERIOUS ADVERSE EVENTS IN SECOND COHORT
Source text: ID:nGNX8xlZdy
Further company coverage: CMND.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.